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ABSTRACT
Heart failure patients are burdened with a variety of pharmacologic and self-care
interventions. Diuretic therapy and fluid restriction can cause thirst and dry mouth,
which decrease quality of life and adherence to medical recommendations. Prior research
has examined saliva stimulants and substitutes to treat thirst and dry mouth in other
populations, but has not applied these therapies in heart failure. We propose that
chewing gum will decrease thirst to a greater extent than artificial saliva in heart
failure patients when compared to baseline. A randomized controlled crossover trial
between chewing gum and artificial saliva will be conducted with each intervention
lasting two weeks. As thirst is a distressing symptom caused by standard heart failure
care and has gone essentially unaddressed, effective treatment of thirst in this population
has the potential to increase quality of life and adherence to lifesaving pharmacologic and
self-care interventions.
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CHAPTER 1: Introduction
1.1 Background
Heart failure (HF) affects over 5.1 million Americans and the prevalence of the
disease is increasing. The American Heart Association projects that the total number of
Americans living with heart failure will increase 46% from 2012 to 2030. This disease is
extremely costly financially as well as in terms of morbidity and mortality. In 2012 alone
the direct cost of medical care for HF patients of all ages was $20.9 billion, and that
amount is expected to increase to $53.1 billion by 2030.1 Hospitalization for Acute
Decompensated Heart Failure (ADHF) is responsible for 80% of this cost, is the leading
cause of hospitalization in the United States, and is associated with a 50%, five-year
mortality rate.1,2 Increasing size and age of the population, prevalence of the disease,
healthcare cost inflation, and high morbidity and mortality has made research on the
treatment of HF a top priority.
HF is a chronic and progressive syndrome most often occurring in patients over
the age of 65 as a result of cardiovascular injury from myocardial infarction or
hypertension, eventually causing remodeling of the myocardium.3 This results in an
inability of the ventricles to properly fill with or eject blood, lowering cardiac output to a
point where there is inadequate blood supply to meet circulatory and metabolic
demands.2,3 The body responds by up-regulating the sympathetic nervous system, reninangiotensin-aldosterone system, and vasopressin axis to increase cardiac output. Chronic
activation of these neurohormonal pathways eventually has the opposite effect, with
excessive retention of fluid and sodium causing a paradoxical decline in cardiac output.2
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This causes the common signs and symptoms of volume overload that often lead to
hospitalization such as dyspnea, weight gain, cough, fatigue, and lower extremity edema.3
Patients with HF are burdened with a substantial number of pharmacologic and
self-care interventions to remove fluid and prevent ADHF exacerbations. Medications
include diuretics to remove excess fluid, angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers to slow the remodeling process in the ventricles, and betaadrenergic blockers to reduce myocardial oxygen demand. All together, these
interventions are directed to improve symptoms and survival. Self-care practices are
emphasized in this population as a way to avoid exacerbation, and these include a low
sodium and fluid-restricted diet, close monitoring of symptoms and daily weights,
appropriate response to new onset of symptoms or weight gain, and adherence to
prescribed treatments, which are often numerous and complicated.3
For many HF patients, consequences of treatment include secondary symptoms
that lead to decreased quality of life. In clinical practice, bothersome thirst is one
symptom that nurses and clinicians often encounter in HF patients. HF patients
experience a unique combination of factors contributing to the symptom of thirst and dry
mouth. Prolonged neurohormonal activation that occurs in HF, including increased
vasopressin and angiotensin II, activates central thirst mechanisms. Diuretics contribute
to thirst by initiating loss of body water, increase in plasma osmolality, and xerostomia,
all of which trigger a desire to drink.4,5 Fluid restriction is a long-standing pillar of selfcare in HF, with conflicting evidence on its utility, that is correlated with increased
perception of thirst. Some recent studies have suggested fluid restriction has no benefit
over liberal fluid intake in terms of weight loss, physical capacity, hospitalization, or
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mortality. 6,7,8 Others cite poor adherence to fluid restriction as a common precipitant for
readmission to hospital, a measure of morbidity in HF.4 In 2013 Philipson et al.
conducted a randomized controlled trial with 90 stable HF patients and found that
patients on a fluid and sodium restricted diet had significantly better outcomes in New
York Heart Association (NYHA) HF functional class and leg edema after 12 weeks
compared to controls. Interestingly, thirst was not significantly different between groups
but this may have been due to insufficient power to detect a difference.8 Despite
inconclusive results on the importance of fluid restriction, it is a commonly used self-care
intervention that contributes to the problem of thirst in HF.
Thirst is described as a sensation causing a powerful urge to drink.5 Xerostomia is
an element of thirst that may also alter taste, impair dental health, and make speaking
difficult.6 It is associated with hyposalivation which is a significant risk factor for dental
disease.9 The existing studies on HF patients have aimed to describe how thirst is
perceived and determine which subset of this population struggles with it the most. A
review of the literature suggests that younger age, male sex, higher body mass index
(BMI), and higher NYHA classification all correlate to higher likelihood of experiencing
thirst.10
The greatest impact of thirst in HF that has been noted in the literature to date is
on quality of life. A descriptive pilot study by Reilly et al. (2010)11 on 25 stable HF
patients aimed at identifying relationships between thirst, fluid intake, and quality of life
found that thirst is an issue in patients attempting to follow fluid restricted diets, is
indirectly correlated with quality of life, and consistently correlates with all subscales of a
HF symptom scale. A 2013 systematic literature review was conducted by Waldreus et
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al.5 of original research in HF patients, with thirst as a primary or secondary outcome
measure, or a patient statement regarding thirst in the results section. They found
descriptions of thirst in stable HF patients that included terminology such as “enormously
annoying”, “irresistible”, “unquenchable”, and “preoccupying”. More importantly, many
studies in the review reported that patients found the only way to alleviate these feelings
was to drink more than their fluid restriction allowed. This can lead to a sense of blame
for their condition and decreased quality of life.

1.2 Statement of the Problem
The primary barrier to research on thirst is that it is a subjective symptom,
experienced and described differently by different people. The Symptom Management
Model developed at the University of California San Francisco states that to completely
evaluate the experience of a symptom, the four qualities of distress, duration, frequency,
and intensity must be assessed12. Currently, there is no framework specifically designed
to evaluate thirst. A number of studies have attempted to evaluate thirst in HF, but a
2014 literature review conducted by Allida et al.12 found that no single study adequately
assessed all four qualities of thirst, with frequency and distress being the most often
overlooked. Moreover, there are only three tools designed to assess thirst, all of which
rely on self-report, and none are validated specifically for HF.4 These are the Visual
Analogue Scale (VAS) and the Numeric Rating Scale, which are both commonly used to
evaluate pain and breathlessness. The third is a Thirst Distress Scale (TDS), which has
most commonly been used to evaluate thirst in hemodialysis (HD) patients.12
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As many as 73% of HF patients struggle with fluid restriction for various reasons,
and there are currently no intervention studies aimed at reducing or alleviating thirst in
these patients.5 Providers have suggested that their patients who complain of thirst ingest
cold drinks, ice chips, peppermint, or buttermilk, and consume less sugar, but none of
these remedies have been tested for efficacy.4,5
Thirst management has been most extensively researched in the setting of endstage renal disease among patients undergoing HD. Attention has been focused on
reducing their thirst and xerostomia to help increase compliance with fluid restriction, a
self-care requirement that is also prescribed in this population. Treating these symptoms
may also help avoid excessive interdialytic weight gain (IWG) and associated
complications, and to improve quality of life.12. The main categories of interventions
include saliva stimulants, for example chewing gum, and saliva substitutes. Intervention
studies examining the efficacy of chewing gum and artificial saliva have been
inconclusive but have suggested chewing gum, and to a lesser extent artificial saliva, may
alleviate thirst and dry mouth in HD patients.13,14 These patients preferred chewing gum
over artificial saliva for its ease of use and taste.13 Neither intervention was found to have
an impact on IWG or net fluid intake, but this may have been because of the short time
frame of the interventions. The positive effect of these interventions on alleviating
xerostomia and thirst has also been found in patients with rheumatic disease and
malignancy.15,16 Both chewing gum and artificial saliva are financially reasonable
interventions that have proven to be effective in various populations suffering with thirst,
and could be an effective treatment for heart failure patients with thirst as well.
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1.3 Goals and Objectives
We are proposing a randomized crossover clinical trial, comparing the use of
artificial saliva and chewing gum in a sample of stable HF patients to test effects on
subjective thirst and dry mouth. Mean VAS scores for thirst intensity will be the primary
outcome measure by which we will compare treatments at the end of intervention
periods. The TDS and Xerostomia Inventory (XI) will be used to measure thirst distress
and xerostomia, respectively, as secondary outcomes. Preference for one intervention
over the other will be assessed with two dichotomous questions.

1.4 Hypotheses
1. There will be a difference in thirst intensity (VAS), thirst distress (TDS), and
xerostomia (XI) between the chewing gum group and the artificial saliva group after two
weeks of each intervention.
2. There will be a difference in preference between chewing gum and artificial saliva.

1.5 Definitions
Xerostomia: dry mouth.
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CHAPTER 2: Review of the Literature
2.1 Introduction
An extensive literature search was conducted between August 2015 and June
2016 focusing on thirst in heart failure patients. The aim of the search was to explore the
underlying pathophysiology of thirst in this population, how the symptom of thirst is
measured in clinical research, and to uncover which thirst treatments were effective.
Ovid, Scopus, and PubMed databases were used to access the relevant literature, and the
search terms utilized included heart failure and thirst or xerostomia or dry mouth, thirst
or xerostomia or dry mouth and saliva stimulants or saliva substitutes or mastication or
gum or chew or chewing gum, and heart failure and self care or fluid restriction or
restrict*. Search criteria were limited to “English language” and produced clinical trials,
cross sectional studies, prospective cohorts, systematic literature reviews, and metaanalyses pertaining to HF and thirst, as well as interventions to treat thirst.

2.2 Review of Empirical Studies
This section will present the literature that has been reviewed pertaining to
chewing gum and artificial saliva and their effect on thirst. This relationship has not yet
been studied in HF patients, so literature from other populations suffering from thirst will
be utilized.
2.2a Chewing gum and thirst
Bots et al. (2004)1 completed a randomized clinical trial examining how eight
different sugar free chewing gums affect saliva stimulation using a convenience sample
of 83 healthy dental students from one school in The Netherlands. The group comprised
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41 men and 42 non-pregnant women at an average age of 25 years, taking no medication
besides oral contraceptives. Subjects were randomized into eight different groups to
receive one of eight different gum flavor and shape combinations including Winterfresh,
Peppermint, Sweetmint, or Liquorice, and stick, tab, or pellet shapes. Salivary flow
stimulated by parafilm, a tasteless wax, provided a baseline measurement and chewing
gum-stimulated salivary flow and pH was measured at intervals up to 10 minutes.
MANOVA analysis showed no statistically significant differences between chewing
gums in terms of salivary flow rate; each intervention significantly stimulated salivary
flow compared to baseline within the first minute of chewing, the average increase being
187%. The different gums subsequently exhibited varying rates of declining salivary
flow over time but after 10 minutes had returned to baseline. Salivary pH increased
slightly over the 10-minute period, reaching statistical significance in three out of eight
chewing gums. However, there was no statistically significant difference in pH change
between chewing gums.
A different group of 112 dental students (61 men 23.2±4.1 years of age and 51
women 24.1±3.2 years of age) with the same inclusion and exclusion criteria participated
in a crossover design trial to test preference. Participants tested three of the different
chewing gums that were randomly selected for two days each, and afterward completed
questionnaires with several different VAS on taste, how long participants chewed the
gum, and willingness to use it long-term. Overall, subjects preferred the Peppermint stick
and Spearmint pellet gums significantly to other options.
This study by Bots et al. (2004)1 suggests equal efficacy of chewing gum to
increase salivary flow and pH regardless of flavor, shape, weight, and manufacturer,
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although these variables do seem to influence preference. Subsequent clinical research
has offered a choice of gum flavor to participants in an attempt to bolster compliance.
Since this was a small sample of healthy young adults from one particular school, there is
limited generalizability to our older HF target population. It should also be noted that
Wrigley, a gum manufacturing company that provided the majority of the gum,
sponsored this research.
Jagodzinska et al. (2011)2 conducted a three-month prospective study on the
effect of sugar free chewing gum on thirst, xerostomia, and hydration of 38 stable chronic
HD patients from a dialysis center in Poland. This followed a 2005 crossover trial of
chewing gum vs. artificial saliva by Bots et al.3 that showed chewing gum was effective
in reducing thirst in HD patients over a shorter intervention period of two weeks. Those
included were over 18 years of age, received HD three times weekly for at least three
months, were clinically stable as determined by daily residual diuresis, and had mean
IWG ≥1000 g in the two weeks before the study began. Participants were excluded for
acute infections, poor control of DM, and orodental conditions that could impair
chewing. Baseline characteristics were similar between the study group and reference
group with the exception of IWG, which was significantly greater in the study group.
Participants received chewing gum in the flavor of their choice with instructions to
slowly chew one piece three times daily after meals for a minimum of 20 minutes, and
throughout the day when they perceived thirst or xerostomia. They were given a diary to
record the amount of gum and fluids they consumed daily, and returned empty gum packs
weekly for assessment of compliance.
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Xerostomia and thirst were assessed in a reference group at baseline, and in the
intervention group at baseline, after three months of intervention, and after one month of
follow-up using a non-validated 19 multiple-choice questionnaire. Neither perceived
xerostomia nor thirst was significantly changed from baseline after the intervention or
one month follow-up period. However, for xerostomia management the percentage of
patients who preferred drinking fluids decreased 26% while those who preferred chewing
gum increased 250% (p=.04). Similar trends were seen in thirst management, with a 45%
decrease in the number of patients who preferred drinking fluids and a 380% increase in
the number of patients choosing gum (p=.004). While the majority had chewed gum
prior to the study, only 10% (n=3) had used it to manage symptoms.
There are a variety of limitations in this study design that could account for the
lack of treatment effect. The use of multiple-choice questionnaire rather than a validated
tool for thirst or xerostomia decreases internal validity. Internal validity may also be
decreased by a learning effect of those who had utilized gum to treat thirst previously.
The lengthy treatment period could decrease patient compliance compared with other
similar trials whose interventions lasted a much shorter time, however it did not result in
a high attrition rate (18.5%). Despite being from the same HD unit with identical
inclusion criteria, there was a significant difference in xerostomia and thirst perception at
baseline between intervention and reference groups, which may reflect poor quality of
questionnaire or poor randomization. As patients could not be blinded from chewing gum
use, the study design had to be open which introduces reporting bias. Side effects from
therapy including diarrhea, abdominal pain, and decreased appetite were reported in 52%
of patients, another factor that may have affected compliance. Decreased appetite was the
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most commonly reported side effect, which is problematic in a largely malnourished HD
population but could potentially be an added benefit of chewing gum for thirst in other
settings. Although this was an essentially negative study, the number of patients
accepting chewing gum as an alternative tool to fluids for symptom management was
significant.
Said et al. (2013)4 conducted a quasi-experimental study regarding the effect of
sugar-free chewing gum on xerostomia, thirst, and IWG in HD patients at the Ain Shams
University Specialized Hospital in Cairo, Egypt using the DTI (Dialysis Thirst
Inventory), XI, IWG, and salivary flow rates. A group of 60 adult patients with end-stage
renal disease, on HD for three months or more, and stable in terms of dry weight and
hematocrit were consecutively enrolled and randomized using block randomization 10
patients at a time into evenly divided intervention and control groups. Exclusion criteria
were extensive, and included diabetes mellitus, ischemic heart disease, autoimmune
disease, malignancy in the oral cavity, microscopic evidence of oral infection, periodontal
disease, hemodynamic instability, dementia, anxiety, depression, use of chemotherapy or
radiation, and use of known xerogenic medications including anticholinergics,
antidepressants, antipsychotics, antihistamines, antiparkinson agents, and diuretics. Data
were gathered before and after each dialysis session during the two-week trial. The
chewing gum group received strawberry and peppermint flavored gum with instructions
to chew one to two pieces for over 10 minutes, six times daily and whenever the mouth
felt dry or they felt thirsty.
Kruskal Wallis tests were used to determine if the four main variables changed
significantly across six dialysis sessions over a period of two weeks. XI (0-5) decreased
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significantly in the intervention group (4.60.6 to 1.80.8, p<0.001) and increased in the
control group (3.30.7 to 4.00.9, p=0.03). DTI (0-5) decreased with intervention
(4.30.6 to 1.90.7, p<0.001) and increased with control (2.31.1 to 4.40.8, p<0.001).
IWG (kg) also decreased in the intervention group over time (4.41.2 to 1.80.7,
p<0.001) and increased with no intervention (1.80.5 to 3.01.5, p<0.001). Salivary flow
(mL) rate was stimulated by chewing gum (0.40.1 to 0.80.2, p<0.001) and decreased in
the control group (0.50.2 to 0.40.2, p<0.001).
Chewing gum as an intervention cannot be blinded, and therefore results of the XI
and DTI are subject to some degree of reporting bias. There was a large difference in
IWG between groups at the first HD session (4.41.2 kg in the study group and 1.80.5
kg in the control group) despite having no significant difference in baseline dry weight,
months on HD, age, or sex. Exclusion criteria were extensive, and eliminated those on
any type of drug that could cause thirst or xerostomia as well as those with ischemic heart
disease, both of which are common in the HF population. This may have increased
internal validity of the study by eliminating potential confounders, but it also greatly
limited generalizability.
In 2013 Fan et al.5 conducted an observational study in No. 5 Hospital of
Shanghai dialysis center of 42 maintenance HD patients to assess thirst and xerostomia,
as well as a crossover trial with 11 HD patients over the course of six weeks to test the
effect that chewing gum versus consuming all liquids through a straw has on the same
outcomes. Thirst was measured by VAS and DTI, while VAS and XI measured
xerostomia. Those included were at least 18 years of age, had been on HD a minimum of
five months, and had stable dry weight and hematocrit. Exclusion criteria were
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hospitalization within the past three months, hemodynamic instability preventing
sufficient ultrafiltration, dementia, or other terminal disease. Each intervention lasted
two weeks with a washout period in between. Sugar-free mint flavored gum was given
with instructions to chew a piece for at least 10 minutes, six times daily and additionally
as desired for feelings of dry mouth and thirst. Participants were given 3 mm plastic
straws to drink water through when they had symptoms.
The use of chewing gum significantly decreased measures of both thirst (VAS
70.717.1 to 61.122.0, p=0.038 and DTI 19.33.4 to 14.34.8, p=0.000) and xerostomia
(VAS 54.619.6 to 44.620.0, p=0.001 and XI 32.29.4 to 27.311.7, p=0.001). The use
of straw also had an effect on thirst (VAS 70.717.1 to 59.421.7, p=0.016 and DTI
19.33.4 to 15.65.3, p=0.003) but not on xerostomia. Three-day IWG (kg) decreased
from a baseline of 3.170.89 to 2.880.65 with chewing gum (p=0.017), and to
2.940.71 with straw (p=0.049), yet there was no change in daily or two-day IWG. When
comparing the two treatments directly, the VAS score for xerostomia was significantly
decreased by the use of chewing gum compared to straw (p=0.06) but there was no
difference in VAS for thirst, DTI, XI, IWG, or salivary flow rates.
Unlike prior studies, this study did not show similar trends between salivary flow
and thirst or xerostomia, suggesting that the cause of thirst in this population is more
complicated than decreased saliva. The sample size of the crossover trial could also have
been insufficient to demonstrate the outcomes. Gum and straws were interventions that
made it impossible to blind patients, which may introduce reporting bias, although this
effect is partly mitigated by the crossover design as participants received both. A
decrease in three-day IWG was a new finding compared with prior studies and would
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need to be reevaluated with a longer intervention period in the future. If it is a true
finding it could have further implications on the importance of treating thirst to improve
objective outcomes in addition to subjective symptoms, a benefit that has been suggested
but not supported in previous studies.
2.2b Artificial saliva and thirst
Jellema et al. (2001)6 examined the effect of Xialine®, a xantham gum-based
saliva substitute, versus placebo in a double blind crossover pilot study on radiationinduced xerostomia and related symptoms in patients with head and neck cancer. Those
included had undergone irradiation for head or neck cancer that began at least three
months before the study, had received a minimum radiation dose of 50 Gy to at least 75%
of the parotid glands, suffered from subjective xerostomia, and had a WHO performance
status of 0-2, a common cutoff for research in cancer patients. Patients were excluded on
the basis of alcohol abuse and salivary dysfunction due to other causes, including
medication-induced. A total of 30 patients from the Netherlands (19 of whom were male,
mean age of 59) were randomized to receive either Xialine or placebo for the first week,
then switched and completed a week of the other substance with a one-week washout
period in between interventions. Instructions were to use the substance at least four times
daily. Placebo composition was similar to the intervention but lacked xantham gum, the
active visco-elastic component of Xialine.
A well-validated quality of life questionnaire developed by the European
Organization for Research and Treatment of Cancer (EORTC) and specific to head and
neck cancer, the EORTC QLQ-H&N35, was used in this study to evaluate xerostomia
and related symptoms. The module contains 35 questions, all of which are rated on a
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four-point Likert scale and later converted to a scale of 0-100, with higher numbers
correlating to a higher burden of symptoms. Data were collected at baseline and after
completion of both treatment arms, and mean changes from baseline were compared
using repeated measures analysis of variance. Change from baseline of five or more
points constituted clinically significant improvement or worsening of symptoms.
Xerostomia was the symptom with the highest EORTC QLQ-H&N35 score at
baseline of 84 out of 100, and it improved after Xialine intervention (-14.8) and placebo
(-17.2) with no significant difference between the two (p=0.78). The next highest
baseline score was for sticky saliva at 71, which also improved with Xialine (-10.7) and
placebo (-11.5) a similar amount (p=0.43). Problems with speech mean score at baseline
was 30, and although it was again not a statistically significant between-treatment
difference (p=0.25), it was demonstrated that Xialine improved it to a clinically
significant level (-7.1) whereas placebo did not (-0.6).
Baseline scores were similar at the beginning of each intervention period,
suggesting the washout period was sufficient and the order of interventions did not affect
results. This study failed to detect a treatment difference between Xialine and placebo in
any of the investigated symptoms, but it did show a trend towards Xialine improving
problems with speech more than placebo. Both intervention and placebo improved
xerostomia and the feeling of sticky saliva. The similar effect in these categories could
be due to the similar composition of the two treatments, which would suggest that
xantham gum, considered to be the active ingredient in Xialine, has no additional benefit
over other saliva substitutes and choice of substitute does not alter results. The short
intervention period could also explain their lack of findings. Patients as well as treating
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physicians were able to be blinded thereby decreasing information bias since the
interventions compared were both saliva substitutes, packaged identically, and with
similar composition. The exclusion of patients with salivary dysfunction from
medications is one criterion that focused this study on radiation-induced xerostomia to
increase internal validity, but limits generalizability.
Alpoz et al. (2007)7 examined the efficacy of Xialine versus placebo to treat
xerostomia-related symptoms in a single-blind crossover study in patients suffering from
Sjögren’s Syndrome, an autoimmune disease that decreases the functional capacity of
salivary and lacrimal glands, causing the main symptoms of dry mouth and eyes. A
group of 29 patients age 24-77 (mean=45) being treated at the Ege University Faculty of
Medicine Department of Rheumatology in Turkey were included in the study. They had
diminished salivary function confirmed with salivary flow rates and objective findings of
xerostomia on exam, did not use alcohol or tobacco, and had not tried any other
intervention for symptoms besides water. Patients completed questionnaires with VAS
for 10 different symptoms of dry mouth one hour after first application, and at the end of
days 1, 7, and 14 for each intervention. In this crossover design, all participants used
placebo six times daily for the first 14 days, then after a washout period of seven days,
everyone completed the study with 14 days of Xialine six times daily.
All 10 symptoms of dry mouth decreased with use of Xialine, including burning
tongue (21.04%), continuous dry mouth (4.78%), painful oral mucosa (3.93%),
diminished taste (25.12%), difficulty with mastication (37.39%), difficulty swallowing
(20.93%), the need to sip liquids to aid swallowing (22.95%), difficulty in speaking
(2.38%), dryness at night or upon awakening (2.54%), and frequent need to moisten oral
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mucosa (3.24%). With use of placebo, there was improvement of only continuous dry
mouth (25.42%), difficulty with mastication (27.25%), difficulty swallowing (28.95%),
the need to sip liquids to aid swallowing (43.98%), difficulty in speaking (39.61%),
dryness at night or upon awakening (35.24%), and frequent need to moisten oral mucosa
(33.78%). There was a statistically significant treatment effect favoring Xialine group
compared to placebo in the categories of overall satisfaction (p=0.011), swallowing
(p=0.027), daily liquid consumption (p=0.019), mouth burning (p=0.025), the need to sip
liquids to aid swallowing (p=0.023), and difficulty in speaking (p=0.004). Although
continuous dry mouth improved in more cases following Xialine administration than
placebo, this result was not statistically significant (p=0.061).
The study by Alpoz et al. (2007)7 was designed as a crossover trial, but there was
no randomization and all participants received the interventions in the same sequence,
making it impossible to blind researchers and introducing information bias. This lack of
randomization into two different intervention groups also makes it impossible to rule out
period effect, so there is no guarantee these results are not affected by the order of
intervention. The discussion states that participants were effectively blinded due to
similar color, taste, and packaging of the two treatments, however the composition of this
placebo (plain water with tea) is much thinner than viscous Xialine, making information
bias possible from participants as well. This study was unique in that they used objective
means to confirm presence of salivary gland dysfunction, a strategy that is more relevant
in Sjögren’s Syndrome than other populations. Participants with this disease are typically
younger women (mean age was 45, sex baseline characteristics were not reported), which
decreases applicability of these findings to our target population that is primarily
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composed of older men.
2.2c Chewing gum and artificial saliva
In a prospective randomized open crossover study, Davies (2000)8 compared
efficacy of Saliva Orthana™, a mucin-based artificial saliva spray, with Freedent™ lowtack, sugar-free chewing gum on xerostomia in patients with advanced cancer. It was
conducted in one hospital and one hospice care center in London using both inpatients
and outpatients complaining of xerostomia. Exclusion criteria included Sjögren’s
Syndrome or other salivary gland disorders, radiation-induced xerostomia, and cognitive
impairment. Forty-three patients (mean age 66, range from 32-87 years, 23 of whom
were female) were randomized into the two treatment arms for five days of use, followed
by two days of washout period, and a final five days of the opposite intervention. The
instructions for gum and spray were to use them before each meal and at bedtime, as well
as other times throughout the day if the mouth felt dry. Other saliva stimulants or
substitutes were not allowed to be used during the study. A questionnaire and VAS for
dry mouth were administered at the beginning and end of each treatment period to assess
efficacy.
Mean VAS scores in either group were similar at the beginning of the first
intervention (32.0 mm in the artificial saliva group and 32.5 mm in the chewing gum
group, p=0.95) as well as the second phase of the study (40.7 mm in the artificial saliva
group and 31.9 mm in the chewing gum group, p=0.34). Analysis at conclusion of the
study showed no evidence of period or carry-over effects (unpaired t-test: P = 0.11).
Mean changes in VAS scores were similar; +22.4 mm with the use of artificial saliva and
+30.1 mm with the use of chewing gum (paired t-test: p=0.49). More patients preferred
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gum (69%) than saliva spray (31%) with the most common reason being a feeling that
one was more effective than the other, although these data were not determined to be
statistically significant.
Internal validity is questionable in this study due to a large dropout rate of 30%,
the majority of which was due to death or deterioration in condition, a common issue in
advanced cancer research and likely why the intervention period was kept short. There
was no difference in the number of side effects reported between groups (five from saliva
spray, seven from chewing gum, p=0.75), however the three participants that dropped out
because of side effects were all due to chewing gum (nausea and mouth irritation). The
article reported baseline characteristics on potential confounders such as the use of
dentures and drugs that cause xerostomia but did not exclude them, which increases the
external validity of their results. Oddly, the VAS scale given to patients in this trial had 0
symbolizing the “worst imaginable oral dryness” and 100 symbolizing “no oral dryness”,
which is the opposite of how this common scale is typically implemented. This could
have confused participants who were familiar with this type of scale, potentially
influencing results.
In 2005, Bots et al.3 conducted a randomized crossover trial with repeated
measures, comparing the efficacy and preference of Freedent chewing gum versus
Xialine in HD patients. A total of 89 patients were randomized to receive one of the two
interventions to use at least six times daily for two weeks, followed by two weeks using
the other intervention in the same manner, with a two-week washout period in between.
Inclusion criteria were at least three months on HD, at least 18 years of age, and being
mentally and physically capable of completing the study. After 27% of participants
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dropped out, a total of 65 patients (42 men, 23 women, mean age 54.65) completed the
study. IWG, salivary flow rates, XI and DTI were measured at baseline and after each
treatment period.
Chewing gum decreased the XI score from 29.9 to 28.1 (-1.8 difference,
p=0.005). Saliva substitute decreased the XI score from 29.9 to 29.0 (-0.9), which was
not a significant change. This was a 50% greater treatment effect of chewing gum vs.
artificial saliva on XI (p=0.024). Perceived thirst as measured by the DTI significantly
improved with chewing gum (p<0.05) from 16.6 to 15.4 (-1.2) and saliva substitute from
16.6 to 15.5 (-1.1). This was an 8% greater treatment effect of chewing gum vs. artificial
saliva (p=0.015). IWG and salivary flow were unchanged by either intervention. Age,
sex, and dentures had no effect on response to treatment. At the end of both treatment
periods, a questionnaire was used to assess efficacy and preference. Chewing gum was
significantly superior to Xialine in each category, including ease of use, effect on thirst,
effect on dry mouth, judgment of taste, benefit received, and willingness to use the
therapy for a longer time period. In a dichotomous assessment of preference, 60%
preferred chewing gum and 15.4% preferred Xialine (p<0.001), while the rest did not
report a preference or had no preference.
At baseline, data were stratified by gender, age (≤65 or >65), residual urine output
(yes/no), and full dentures (yes/no), and there were significant differences found in IWG,
XI, and DTI when looking at age and residual urine output. Younger age and no residual
urine output, which correlates with more advanced CKD, were associated with high XI,
DTI, and IWG. Some other studies chose to exclude denture wearers, but by including
them Bots et al.3 was able to show they did not have an effect on response to either gum
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or saliva therapy. Consistent with the study by Bots et al. (2004)1, giving participants a
choice of gum flavor did not affect outcomes and is assumed to have increased
compliance. The results only included data from the 73% of participants that completed
the study, which would not alter characteristics between groups in a crossover design
study but may introduce bias. No participant dropped out of the study due to side effects,
but unpleasant taste, nausea, irritation of the oral mucosa, diarrhea, sensitivity of the jaw
and teeth, and fatigue of muscles were reported.

2.3 Review of Possible Confounding Variables
2.3a Demographics
Age and sex are basic demographics that are reported in all studies to assess their
potential influence on results, including those on thirst in HF. In 2011, Waldreus et al.9
conducted a cohort investigation of thirst in 48 HF patients, 65 years of age or older, half
of whom were admitted to the hospital with acute decompensated HF, while the other
half were admitted to the hospital for treatment of an acute illness other than HF. Thirst
as assessed by VAS was much higher in elderly patients with worsening HF (median 75
mm, interquartile range 56-90) compared with acutely ill elderly patients without HF
(median 25 mm, 11-40; p<0.0001). They found that age, gender, and diuretic medications
were not significant predictors of thirst in either the HF or control group in this specific
population of elderly people admitted to the hospital. The same investigators conducted a
descriptive prospective study in 201410 designed to assess the factors associated with
persistent thirst in HF patients over an 18-month period following hospitalization for HF
exacerbation. Persistent thirst was found in 121 (19%) of the total 649 patients, and this
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subpopulation was significantly younger (mean age 64 years versus 70 years, p<0.01),
more likely to be male (75%, p<0.01), more likely to be on diuretic medications (99%
versus 95%, p=0.03), and had a greater number of HF symptoms at 1 month (four versus
three, p<0.01), a higher mean BMI (29 kg/m2 compared with 27 kg/m2 , p<0.01), and
more depressive symptoms as assessed by the Center for Epidemiological Studies
Depression Scale (median total score 14.5 versus 12.0, p=0.02). Ejection fraction,
NYHA class, N-terminal pro-B-type natriuretic peptide, presence of diabetes or
hypertension, and practice of fluid restriction were not significantly different among
those who suffered from persistent thirst.
2.3b Fluid restriction
Holst et al. (2008)11 conducted a randomized crossover study of 74 patients who
had improved from NYHA class III-IV HF to a stable condition in order to investigate
the effects of a fluid restricted diet on thirst and other various outcomes. Fluid restriction
and liberal fluid intake (control) interventions lasted for 16 weeks each. Median sense of
thirst on VAS at the end of the intervention was 51 mm (interquartile range 16-69) in the
fluid restricted group compared to 23 mm (6-53) for the liberal fluid intake group
(p<0.001). Median VAS score for difficulties to adhere to fluid prescription was 23 mm
(5-56) with fluid restriction, compared to 6 mm (1-24) with liberal fluid intake (p<0.001).
In 2013, Philipson et al. 12 conducted a 12-week randomized controlled intervention
trial of 97 stable HF patients on daily furosemide - a diuretic, comparing the effect of
fluid restricted diet with no specific restrictions, on a number of outcomes including
thirst. In this trial, difference in change between groups in regard to thirst, as measured by
VAS 1-10mm, was not statistically significant (4.2 to 4.4 during the intervention
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compared to 4.4 to 5.2 during the control, p=0.06). As stated previously, Waldreus et al.
(2011)9 also found that the presence of persistent thirst was not correlated with fluid
restriction. Inconclusive data such as these from the body of literature on the benefits and
consequences of fluid restriction is why it remains a controversial, although often used,
self-care measure in patients with HF as well as a possible confounder of thirst
assessment.
2.3c Heart failure classification and severity
It is expected that the bothersome symptoms of thirst and dry mouth would
increase in severity in a parallel fashion with disease severity, but this has yet to be
clearly demonstrated in HF. Waldreus et al. (2011)9 demonstrated a trend in worsening
thirst with increased NYHA functional classification in patients over 65 admitted to the
hospital for ADHF. However, the same investigators later reported data10 suggesting that
NYHA class, ejection fraction, and N-terminal pro-B-type natriuretic peptide were
unchanged between those who suffered from persistent thirst and those who did not. A
pilot study conducted by Reilly et al. (2010)13 on thirst and quality of life in HF found
that thirst distress is moderately correlated to all subscales on the Heart Failure Symptom
Survey. These consisted of frequency (r = .545, p = .005), severity (r = .538, p = .006),
interference with physical activity (r = .605, p = .001), and interference with enjoyment
of life (r = .552, p = .004). Some studies choose to stratify their data by NYHA class
while others simply record this information in their baseline characteristics. Thus, all do
include NYHA class in analyses, as it is a likely source of confounding despite a lack of
clear evidence.
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2.3d Preference
Preference for chewing gum or saliva substitute may have a confounding effect on
the self-report scales used to quantify thirst and xerostomia. With these different
interventions, it is impossible to blind participants to eliminate this effect. The question
of preference is also closely related to compliance, another potential confounder.
Therefore, reporting patient preference along with thirst outcomes is of utmost
importance. The hypothesis of our proposed study is that irrespective of the results of the
primary outcome, more patients will prefer chewing gum to artificial saliva based on
similar findings throughout our literature review.2,3,8

2.4 Review of Relevant Methodology
Detailed methodology of the proposed study is outlined in Chapter 3. This section
is designed to provide a review of relevant study methods. It is impossible to compare
methodology used in studies on the effect of artificial saliva and chewing gum on thirst in
heart failure patients, as none exist in the literature.
2.4a Design
In a 2011 Cochrane review by Furness et al.14 on topical therapies for dry mouth
management, 29 out of the 36 included studies were crossover designs, with a washout
period between interventions. Research on thirst lends itself to this study design as it is a
stable, slowly changing condition, and the topical therapies designed to alleviate it have
no known lasting effects and are considered reversible in a relatively short time frame,
especially when a washout period is utilized. An added benefit of this design is that it
decreases problems with confounding variables between groups, since each participant is
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included in both arms of the trial, and thereby serves as their own control. This allows for
statistical analyses that assume randomization, and gives participants the ability to
directly compare preference. It also has unique characteristics for statistical analysis. The
sample size needed to power a study and meet the same criteria in terms of type I and II
errors is lower than studies with parallel groups, making it a statistically efficient design.
There are some pitfalls of this type of study as well, some of which can be avoided with
proper design. There can be unintended effects based on the order of intervention
(treatment effect), and carry-over effects from one intervention period to another, for
example, learning the study procedures over time (period effect). These can be avoided if
the therapies being tested have short-term efficacy and a long enough washout period is
used between interventions. Analysis can be performed after the fact to ensure the results
are free from these unintended effects.15
2.4b Setting and selection criteria
The proposed study will take place in outpatient HF clinics in Connecticut. Adults
≥ 18 years of age with evidence of structural underlying heart disease who fall into
NHYA functional class II-IV will be eligible to participate. Patients included will be in a
stable condition as determined by lack of symptoms or physical exam findings of fluid
overload, and no medication adjustments in the preceding two weeks. Prior studies on
thirst in this population had participants recruited at time of discharge from
hospitalization for a HF exacerbation, but as our study aims to capture information from a
more stable sample, hospitalization within the past month for any reason will be an
exclusion criterion.11,12,16 Patients who are not able to chew gum, apply a salivary spray,
or complete written surveys will be excluded.
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2.4c Interventions
The most common interventions for thirst are topical and include either saliva
substitutes (viscous material applied to the oral mucosa in the form of sprays, gels, oils,
mouthwashes, or pills, also referred to as “palliative care”) or saliva stimulants (lozenges,
chewing gum, or toothpaste which may contain medication). Less commonly,
interventional studies have included acupuncture, electrostimulation, and systemic
therapy such as oral pilocarpine.14
Sugar free chewing gum and artificial saliva spray will comprise the two
treatment arms in the proposed study. Sugar free chewing gum contains sugar
substitutes, such as bulk sweeteners like xylitol, mannitol, and sorbitol, or intense
sweeteners like aspartame; each of these have been shown to be non-cariogenic.17 A
number of studies have demonstrated that chewing gum increases salivary flow for a
limited time due to a number of stimuli it provides, including aroma, flavor, taste, and
mastication.2 It has also been demonstrated that increased salivary flow enhances the
buffering ability of saliva, so chewing gum can effectively neutralize the decrease in
saliva and plaque pH that occurs after meals, thereby combating cariogenic acid
production.17 As discussed previously, Bots et al. (2004)1 conducted a preliminary study
on salivary stimulation and preference of eight different chewing gums, seven of which
were Wm. Wrigley Jr. brand. Each gum, despite flavor and shape, stimulated salivary
flow to the same extent and for the same time period, but patients had a variety of gum
preferences. Based on these results, a number of studies that followed gave participants a
choice of flavor in the hope of improving compliance, a practice that we will continue in
the proposed study.2,3
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Different categories and brands of saliva substitutes have been compared and used
in various trials, but data remain inconclusive regarding which is the most effective, or if
there is any benefit to them over placebo.18 Xialine is a specific brand of saliva substitute
that has been utilized most in the literature reviewed, and this will be used in the
proposed study. Like all saliva substitutes, it provides a coating over the oral mucosa to
help retain moisture. It contains 0.92% polysaccharide xanthan gum as its active
ingredient (giving it visco-elastic properties similar to human saliva), as well as sodium
fluoride for tooth mineralization.3,6
The intervention period of two weeks per treatment with a two-week washout
period in-between was chosen, as it was the most common length of intervention and
washout found in studies with positive results.3-5,7 Longer intervention periods such as
three months in the case of Jagodzinska et al. (2011)2 and shorter time frames such as one
week in Jellema et al. (2001)6 or five days in Davies (2000)8 showed no treatment effect
of intervention versus placebo or between two interventions.
2.4d Outcome measurement
The VAS is a scale commonly used to evaluate pain and breathlessness, and the
one that has most commonly been used in HF to evaluate thirst intensity. A VAS is
characterized by a continuous horizontal line from 0-10 or 0-100 mm with verbal
descriptors on either end, and typically the left side of the line indicates lack of a
symptom while the right indicates the greatest symptom level possible.7 Waldreus et al.
(2013)19 and Allida et al. (2014)20 conducted similar reviews of original studies in
patients with HF using thirst as an outcome measure. In total, five of the 11 studies
included used the VAS, making it the most common scale utilized. It is commonly
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employed in other populations suffering from thirst and dry mouth including HD,
Sjögren’s Syndrome, and head and neck radiation.5,14,21 While it has not been specifically
validated to evaluate thirst intensity in HF, its consistent use in research for purposes of
assessing characteristics associated with thirst makes it the best tool to derive a treatment
effect from in order to calculate sample size, and to assess our primary outcome in the
proposed study.
The TDS is a scale that has been validated in HD patients to assess thirst distress,
defined as the degree to which a person is bothered by thirst or its associated discomfort.
It was developed in 2002 by Janet Welch22 and is a six-item tool, each with a five-point
Likert scale where 1 corresponds to strongly disagree and 5 to strongly agree, for a total
possible score ranging from 6-30. In the development of the TDS, Welch used a panel of
experts to establish content validity and a convenience sample of 247 adults receiving
outpatient HD to test the item pool. Cronbach’s alpha was 0.78, considered to be
satisfactory in terms of reliability. Confirmatory and exploratory factor analysis, as well
as observed associations between thirst distress, thirst intensity, and IWG supported
construct validity. While it is not included as part of the TDS, Welch used a VAS for
thirst intensity in conjunction with TDS for a more global assessment of the symptom.22
Jacob et al. performed a follow-up study in 2004 which again supported a correlation
between TDS and IWG in HD patients.23 Due to this evidence of validity and reliability
in HD, the TDS has been used commonly in this population but can also be found in
recent articles on HF as this population lacks a specific validated scale. Reilly et al.13
used the TDS as the only measurement of thirst in a 2010 pilot study on thirst and quality
of life in HF with mean of 15.6 (SD 7.7). They reported a moderate correlation between
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all the symptoms of the Heart Failure Symptom Survey and the TDS: frequency (r = .545,
p = .005), severity (r = .538, p = .006), interference with physical activity (r = .605, p =
.001), and interference with enjoyment of life (r = .552, p = .004).13,19 This was the only
study to use this scale in a 2014 comprehensive review of articles using subjective
measures of thirst as a primary or secondary endpoint in HF patients conducted by Allida
et al.20, while four of the six studies included used the VAS. The discussion at the end of
this review again suggested combining multiple scales for more thorough data.
XI is a tool composed of 11 questions relating to the symptom of dry mouth, each
with a corresponding five-point Likert scale ranging from 1 (never) to 5 (very often).
These scores are summed to total a final XI score between 11 and 55. It has since been
validated in HD, but was originally developed and validated in the dental community by
Thomson et al. (1999).5,24 Initially, 19 questions were compiled to evaluate xerostomia
based on a combination of literature review, and interviews conducted in a convenience
sample of four long-term sufferers of xerostomia. Further analysis divided these
questions into two different scales, one being the 11-question XI score (Cronbach’s alpha
of 0.84). The validity of the XI was then tested in a sample of subjects suffering from
xerostomia who were part of a five-year South Australian Dental Longitudinal Study. XI
questionnaires were completed and returned by 649 participants, and were compared with
a standard single xerostomia question (“How often does your mouth feel dry?” Response
options: “Never”, “Occasionally”, “Frequently”, “Always”), as well as salivary flow data.
One-way ANOVA analysis determined that mean XI scores differed significantly
between each of the four responses on the standard single xerostomia question
(p<0.0001), with an overall correlation between the two data collection tools of 0.42
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(p<0.01). Correlation between XI score and resting whole salivary flow rates was low (r=
-0.05) and not statistically significant.
This tool has since been widely utilized in a variety of populations, most
commonly in populations with direct salivary gland involvement such as Sjögren’s
Syndrome and those with head and neck cancer irradiation. However, it has also been
used in research on thirst and dry mouth in HD patients, a population with a more
complex cause of these symptoms. For example, Bots et al. (2005)3 found a positive
treatment effect of chewing gum on xerostomia based on the XI. Salivary flow was
unaffected, consistent with initial data from Thomson et al.24.
Salivary flow rates are commonly measured in studies on thirst as a form of
objective data, in particular when saliva stimulants such as chewing gum are used.
Salivary flow is diminished in autoimmune diseases such as Sjögren’s Syndrome and
with radiation-induced damage to the salivary glands, or with certain medications, but is
not known to be affected in HD or HF. Said et al. (2013)4 utilized a sample of HD
patients who demonstrated improved xerostomia, thirst, and salivary flow with the use of
chewing gum. However, as stated previously, Thomson et al. (1999)24, Bots et al.
(2005)3, and Fan et al. (2013)5 found no correlation between XI and salivary flow, and a
review on xerostomia management by Visvanathan et al. (2009)25 concluded that salivary
flow rates are highly variable and do not tend to correlate to subjective symptoms.
Each of the aforementioned scales (VAS for thirst intensity, TDS, and XI)
evaluates a different part of the symptom in question. Since there is no clear gold
standard and each measure contributes unique information, they will each be included in
our proposed study. We will however, not include salivary flow as an outcome of thirst
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since this is an inherently subjective symptom that has not been shown to correlate highly
with salivary flow rates.
2.4e Follow-up
It has been demonstrated in prior research that the effect of saliva substitutes and
stimulants occurs quickly, and common practice has been to collect relevant data at
baseline as well as prior to and immediately following an intervention with no additional
followup.3,7,8 Jagodzinska et al. (2011)2 was an exception to this practice, and found no
change in thirst or xerostomia one month following the completion of a chewing gum
intervention. Therefore, there will be no follow-up period in our proposed study.

2.5 Conclusion
Several studies have shown chewing gum to be effective at alleviating thirst and
xerostomia due to a variety of causes in different populations.2-5,7,8 A more limited body
of research has shown that saliva substitutes may alleviate these symptoms as well.3,6-8
There were two studies reviewed that provide a direct comparison of these interventions.
Davies (2000)8 found that both Saliva Orthana salivary substitute and sugar-free chewing
gum significantly alleviated thirst as measured by VAS in advanced cancer patients, with
no between-treatment difference. There was an overall preference for chewing gum, but
this was not a statistically significant finding. Bots et al. (2005)3 found that only chewing
gum decreased xerostomia significantly, and there was a 50% greater treatment effect of
chewing gum over Xialine on the XI. For thirst, both interventions significantly
decreased the DTI score but there was still a significant 8% greater treatment effect of
chewing gum over artificial saliva. In that study, preference for chewing gum was found
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to be statistically significant. Due to the demonstrated lack of interventional studies at
alleviating thirst in HF, our proposed study will integrate data from clinical trials in other
populations with background information on the problem of thirst in HF in order to
investigate the potential benefit that chewing gum and artificial saliva may have.
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CHAPTER 3: Study Methods
3.1 Study Design
The proposed study will be a prospective, randomized, single-blinded crossover
study comparing the efficacy of Freedent sugar-free chewing gum vs. Xialine salivary
substitute spray in decreasing thirst and dry mouth in stable adult HF patients suffering
from these symptoms.

3.2 Study Population and Sampling
A sample of 120 volunteers will be recruited from the outpatient HF clinics of
Yale-New Haven Hospital, Bridgeport Hospital, Hartford Hospital, and the University of
Connecticut Health Center. These clinics combined serve over 1,000 HF patients.
Patients who report the symptom of thirst or xerostomia, meet the criteria listed below,
and are willing to participate in the study will be enrolled.
Inclusion criteria include ≥18 years of age, previous diagnosis of HF documented
in the electronic medical record, NYHA functional classification II-IV, and willing and
able to complete survey instruments. Exclusion criteria include current signs or
symptoms of volume overload, medication adjustment in the prior two weeks,
hospitalization for any reason in the prior month, current use of methods besides water
for thirst or xerostomia symptom management, Sjögren’s Syndrome or other salivary
gland disorder, prior radiation for head or neck cancer, inability to chew gum or
personally apply saliva spray, and non-English speaking or reading. Individuals who have
had medication adjustments in the prior two weeks or been hospitalized in the prior
month will be re-contacted after the requisite time period has passed.
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3.3 Subject Protection and Confidentiality
Protocol application will be submitted to the Yale Human Investigation
Committee (HIC) and the Yale Institutional Review Board (IRB) for study approval.
Upon approval, letters will be sent to each collaborative site for study protocol approval
via their own institution’s IRB. Approval letters will be returned and kept on file at the
Yale HIC. All members of the research team and outside consultants involved in the
study will complete the Health Insurance Portability and Accountability Act (HIPAA)
privacy training and the Yale Human Subjects Protection Training prior to study
initiation. Only after all of these requirements have been met will the study begin.
Identity and health information of participants will remain confidential. HIPAA
policy will be strictly enforced, and each participant will be assigned a unique number
with no personal identifiers, by which they are identified throughout the entire study.
Written informed consent will be obtained, following standard IRB guidelines.
(Appendix J).

3.4 Recruitment
In each participating center, flyers indicating the purpose of the study with contact
information for a research associate responsible for telephone screening will be posted in
the waiting area and examination rooms (Appendix A). Telephone screening will begin
by confirming that the patient feels thirsty or feels their mouth is dry. A positive
response to either of these questions will trigger application of the inclusion and
exclusion criteria to determine eligibility. If eligible, potential candidates will be
provided with the informed consent form. Given the combined numbers of patients seen
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weekly in the designated practices, we anticipate that study recruitment will last for
approximately 26 weeks.

3.5 Study Variables and Measures
3.5a Independent variables
Two interventions will be directly compared in this study: 1) Freedent (Wm
Wrigley Jr Co., Chicago, IL, USA), a low-tack, sugar-free chewing gum, will be provided
to patients with a choice of three flavors (Sweetmint, Winterfresh, and Peppermint) to
optimize compliance, with instructions to use one to two pieces of gum at a time, at least
four times daily (before each meal, before bedtime, and any other time they have
symptoms), chewing at least 10 minutes each time; and 2) Xialine (Lommerse Pharma
B.V., Oss, The Netherlands), a polysaccharide xantham gum-based salivary substitute
with visco-elastic properties similar to human saliva, will be provided in spray bottle
(50mL) form, with instructions to apply the spray to coat the oral mucosa at least four
times daily (before each meal, before bedtime, and any other time they have symptoms).
The use of interventions for thirst other than those provided, or water, will be
discouraged.
3.5b Dependent variables
The primary outcome of the proposed study will be change in thirst intensity, and
the VAS will be the primary outcome measure to compare the effect of each treatment
(Appendix D). The VAS is a horizontal line 100 mm in length with the left end
indicating absence of thirst and the right end indicating the highest intensity of thirst.
Patients will mark the line at the point that most accurately represents their perception of
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the symptom in that moment, and the distance in mm from the left end of the scale will
be used as the VAS score.
The TDS will be used to measure thirst distress (Appendix E), and the XI will
measure xerostomia (Appendix F), both as secondary outcomes.
Each scale will be administered at baseline and before and after each treatment
period, for a total of five assessments over time. Finally, preference for treatment will be
assessed at the completion of the second intervention period with a series of two
dichotomous questions; “Do you have a preference for either chewing gum or artificial
saliva?” (yes/no), followed by “Which do you prefer?” (chewing gum/artificial saliva) if
the initial response is “yes” (Appendix B).
3.5c Baseline variables
Additional variables to be collected at baseline will include age, gender, race,
NHYA functional classification, alcohol/cigarette/denture use (yes/no), diuretic
medication (yes/no), and fluid restriction (yes/no). (Appendix B)

3.6 Methodology Considerations
3.6a Assignment of Interventions
Assignment of participants to either chewing gum or artificial saliva for the initial
intervention period will be accomplished via computer-generated random numbers,
assigning participants in a 1:1 ratio to either order of interventions. An independent
researcher who is not otherwise affiliated with the study will be responsible for this
process. The initial intervention will last for a period of two weeks, followed by a
washout period of two weeks in which participants do not use either intervention, and
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finally each participant will complete another two-week period of the other intervention
to which they were not originally randomized.
3.6b Blinding of Intervention
Due to the nature of the different treatment arms, blinding of participants to the
order in which they receive interventions is not feasible. All data collectors will be
blinded to condition. Participants will be instructed to not discuss treatment allocation
with one another or members of the research team.
3.6c Blinding of Outcome
This study will utilize single blinding, as all researchers collecting and assessing
data will be blinded to the order of intervention participants received.
3.6d Adherence
Adherence to treatment will be assessed at the end of each intervention period
using a questionnaire, for a total of two adherence assessments (Appendix C). The
questionnaire will also ask participants to record any tools, other than the gum or spray
provided, that they used to treat thirst or xerostomia during the trial. Due to the benign
nature of the proposed interventions, few adverse events are expected but any that occur
will be recorded and monitored with the adherence checkpoints. These will be reported
in list form in the final results.

3.7 Data Collection
Initial collection of baseline data at the beginning of the study will be
accomplished by a combination of self-administered questionnaires, patient interviews,
and medical record review to ensure accuracy of information obtained. Age, gender,
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race, use of alcohol, use of cigarettes, use of dentures, and practice of fluid restriction
will be obtained upon patient interview. Diuretic use will be assessed by a combination of
medical record review and patient interview to ensure there is a prescription as well as
adherence in taking the medication before answering “yes” to this question. To ensure
consistency, one blinded researcher will be responsible for determining NYHA functional
classification based on patient interview for all participants as this involves some
subjectivity (Appendix G). Data regarding thirst and xerostomia will be collected by selfadministered questionnaire at baseline and before and after each treatment period for a
total of five data points over time. The two questions regarding preference will be
administered once at the completion of the second intervention period.

3.8 Sample Size Calculation
The study will utilize a two-tailed test and alpha of 5%, beta of 20%, and power
of 80%. Mean score on the VAS will be compared between the two treatments using
values assessed at the end of the respective treatment conditions. Assuming a 10-point
difference on the primary outcome between interventions, power analysis indicates the
need for 200 participants. However, when a conversion is completed to account for the
statistical efficiency of a crossover design, the result is a sample size of 50 participants
per treatment arm, for a total of 100 participants. A dropout rate of 20% is expected
based on previous research. When this is taken into account, the adjusted sample size
requires 60 participants per treatment arm, for a total of 120 participants. Additional
detail on sample size calculation is provided in Appendix I.
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3.9 Analyses
We assume the absence of order effects given that, 1) each treatment is
known to not have carryover effects on any of the dependent variables, and 2) we are
utilizing a washout period between implementation of treatments. We will nonetheless
test whether washout is successful by comparing values for each dependent variable at
the end of baseline vs. the end of washout (Appendix H).1
Assuming that washout is successful, a two sample t-test will be used to compare
the values for each dependent variable (e.g., VAS thirst) at the end of the treatment
conditions. If however we find that washout was not successful, we will utilize change
scores as the dependent variable (e.g., change in VAS thirst from end of initial baseline to
end of first treatment, end of washout to end of second treatment). These change scores
will then be combined in t-test comparisons of the two treatments. Superiority of either
treatment over the other will be demonstrated by a significant t-value. Chi-square
analysis will be used in the same manner for the dichotomous dependent variable,
treatment preference.
Additional, exploratory analyses will be conducted to determine whether subject
level variables (e.g., gender, race, age (≤65 or >65), NHYA functional classification,
alcohol/ cigarette/ denture use (yes/no), diuretic medication (yes/no), and fluid restriction
(yes/no)) influence superiority of one treatment vs. the other. Given the categorical nature
of these variables, chi-square tests will be used. In the case of missing data, the analysis
will only include results from those participants who completed the entire study protocol
in an effort to maintain equality in sequence groups, although all of the available data will
be presented in the document.
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3.10 Timeline and Resources
Recruitment will begin in January of 2017 and is expected to take about 26
weeks. The study will be initiated in a rolling manner, and analysis will be completed
immediately after all 120 participants have completed the study.
The Principal Investigator of this study will be Matthew M. Burg, PhD and CoPrincipal Investigator will be Alison Robb, PA-SII. One research associate will be
needed to field telephone calls in order to screen and enroll participants. One independent
researcher will be responsible for the computer-generated randomization and allocation
process, and will not be involved in any other aspect of the study. One blinded assessor
will collect all data and outcome measurements throughout the study. A statistician not
affiliated with the study in any way will be consulted to assist with data input and
analysis. Required equipment will include the chewing gum and artificial saliva,
computer access for patient EMR review, and the paper flyers and data collection tools.
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CHAPTER 4: Conclusion
4.1 Advantages and Disadvantages
The proposed prospective, randomized, single blinded crossover study comparing
the effect of chewing gum vs. artificial saliva on thirst and xerostomia in HF patients
would be the first of its kind and thus fill a gap in the literature. Since there is no tool
validated to measure thirst or xerostomia in HF, three different self-report scales will
quantify patient perception of different aspects of the complex problem of thirst,
providing a more comprehensive look at the symptom than previous studies. We elected
to forego objective measurements utilized in similar research with other populations as
they did not specifically apply to the disease process of HF, have not been proven to
correlate with symptoms, and distract focus from personal perception of thirst and its
quality of life implications. A single, validated tool to comprehensively evaluate the
symptom of thirst in HF would be a crucial step forward and should be addressed prior to
conducting research subsequent to this study.
Frequency and length of interventions were estimated from previous studies that
demonstrated a positive effect of chewing gum and/or artificial saliva, and tailored to
maximize treatment effect while minimizing lapses in adherence and attrition rates.
Since utilization of these interventions is intended to be long-term in stable HF patients,
the short intervention period may be a limitation of the study. Besides unstable clinical
condition and NYHA class I functional capacity (patients with cardiac disease but
without resulting limitation of physical activity), everyone who reported thirst or
xerostomia at initial screening and was able to utilize both interventions and complete the
outcome measurement surveys was included in the study. The inclusive nature of our
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criteria introduces multiple possible confounders, but allows excellent generalizability to
the general HF population. The multicenter nature of our study adds to external validity
as well. Diuretic therapy and fluid restricted diets are two examples of important
confounding variables specific to our population; these will be assessed at baseline and
not serve as exclusions in this first trial of its kind. Studies examining the effect of
interventions for thirst while stratifying by these variables should be a focus in future
trials.
Crossover study design is consistently utilized in the literature to compare efficacy
of saliva stimulants and substitutes with one another, or with placebo. Potential
limitations of this design include doubling the time frame, carryover effects between
treatments, and failure to use statistical analysis appropriate for the design, but these were
all accounted for in our initial design and analysis process. The numerous advantages of
this design include direct comparison of the chosen interventions, statistical efficiency,
and limiting of confounding variables by having each participant serve as his or her own
control. In addition, the short-term effect of our interventions makes it likely that the
order in which they are utilized will not affect results. These considerations make
crossover design the best option for our study.
A disadvantage of this study is the wide availability and use of one of the
interventions, namely chewing gum. While patients specifically utilizing a substance
other than water for thirst or xerostomia treatment will be excluded from study
participation, some patients will have used chewing gum to treat their thirst in the past.
This may introduce reporting bias and has the potential to skew preference towards
chewing gum, a trend found in previous studies, based on familiarity alone. Although
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chewing gum is readily available to the public, explicit instructions to avoid using either
intervention outside of its assigned two-week intervention period will be given, and
verified with the adherence questionnaire.

4.2 Clinical and Public Health Significance
Over 5.1 million Americans have a diagnosis of HF, a number that is increasing as
the population ages, and many of these patients experience the symptoms of thirst and
dry mouth.1,2 Topical therapies such as saliva substitutes and stimulants have been shown
to be effective and safe for treating thirst in other populations, and would be simple, costeffective solutions to this problem in our target population. Willingness to utilize a
therapy long-term is essential as the benefits of these interventions are short-lived, so
assessment of preference is just as important, if not more important, than data
determining which method decreases thirst to a greater extent. It is our hope that
targeting this long-overlooked symptom in a stable HF population will improve their
symptoms and quality of life. Further implications of these interventions on compliance
with diuretic medications and fluid restricted diets, and ultimately on hospitalization
rates, must be examined after a comprehensive, validated tool for thirst in HF has been
formulated.2,3 As it stands, research on therapies designed to provide relief to HF patients
suffering from thirst are long overdue, and our study aims to meet this need as well as
provide a springboard for further investigation.
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APPENDIX A: Recruitment Flyer

Many heart failure patients suffer from

thirst or dry mouth…

…how about YOU?

If you are interested in participating in a short study to test
simple approaches to treating these symptoms WITHOUT
taking more pills, please call our research assistant at:

315-247-1566

Don’t wait! Availability in this study is limited and not guaranteed
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APPENDIX B: Data

Collection Form

Study Title: Chewing gum and saliva substitute for the treatment of thirst in heart
failure: A crossover trial
Principal Investigators: Matthew M. Burg, PhD and Alison Robb, PA-SII
Participant Identification #: _____________________
Age: _____________________
Gender:

M

F

(Circle one response)

Race: _____________________
Use of alcohol:
Use of cigarettes:
Use of dentures:

Y

N
Y

N

Y

N

Fluid restricted diet:

Y

Diuretic therapy:

Y

N

N

NYHA functional classification:

II

III

VAS (0-100)

IV

TDS (6-30)

XI (11-55)

Baseline:
Start of intervention #1:
End of intervention #1:
Start of intervention #2:
End of intervention #2:
Do you have a preference for one intervention over the other?
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Y

N

If yes, which do you prefer?

Chewing gum

Artificial saliva

APPENDIX C: Adherence Assessment
Participant Identification #: _____________________
In your responses, please do not include any information that would indicate which
intervention you have been using for the past two weeks, or the order in which you
received interventions

Intervention Period #1
1. In the past two weeks, how many days did you fail to use the intervention as
prescribed? ____________________________________________________________
2. In the past two weeks, have you forgotten to take the intervention with you when you
left the house? __________________________________________________________
3. Did you use the intervention as prescribed yesterday? _________________________
4. What other tools (besides water) have you used to treat your thirst and/or dry mouth in
the past two weeks? ______________________________________________________

Intervention Period #2
1. In the past two weeks, how many days did you fail to use the intervention as
prescribed? ____________________________________________________________
2. In the past two weeks, have you forgotten to take the intervention with you when you
left the house? __________________________________________________________
3. Did you use the intervention as prescribed yesterday? _________________________
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4. What other tools (besides water) have you used to treat your thirst and/or dry mouth in
the past two weeks? ______________________________________________________
APPENDIX D: Visual Analogue Scale (VAS)

Image adapted from Millard-Stafford et al., 2012 1

53

APPENDIX E: Thirst Distress Scale (TDS)

Image

adapted

Response options: Strongly disagree (1), moderately disagree (2), neutral (3),
moderately agree (4), strongly agree (5)
from Welch, 2002 2
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APPENDIX F: Xerostomia Inventory (XI) 3
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APPENDIX G: New York Heart Association
Functional Classification of Heart Failure 4
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APPENDIX H: Crossover Study Design Schematic 5
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APPENDIX I: Sample Size Calculation
Sample size calculation, unadjusted for study design

This software developed by David Schoenfeld, Ph.D. (dschoenfeld@partners.org), with support from
the MGH Mallinckrodt General Clinical Research Center. Javascript version developed by REMorse.
http://hedwig.mgh.harvard.edu/sample_size/js/js_crossover_quant.html
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APPENDIX J: Informed Consent Form
COMPOUND AUTHORIZATION AND CONSENT FOR PARTICIPATION IN
THE CHEWING GUM AND ARTIFICIAL SALIVA IN THE TREATMENT OF
THIRST RESEARCH TRIAL
YALE UNIVERSITY SCHOOL OF MEDICINE
Study Title: Chewing gum and saliva substitute for the treatment of thirst in heart
failure: A crossover trial
Principal Investigator: Matthew M. Burg, PhD; Alison Robb, PA-SII
Invitation to Participate and Description of Project
You are invited to take part in a research study designed to look at the effectiveness
of chewing gum and artificial saliva on treating thirst in stable heart failure patients. You
have been asked to take part because you have a diagnosis of heart failure, are clinically
stable with a NYHA functional classification of II-IV, and reported the symptom of “thirst”
or “dry mouth”. This study will be enrolling approximately 120 participants from four
different heart failure clinics in the state of Connecticut.
In order to decide whether or not you wish to be a part of this research study you
should know enough about its risks and benefits to make an informed decision. This
consent form gives you detailed information about the study, which a member of the
research team will discuss with you. This discussion should go over all aspects of this
research: its purpose, the procedures that will be performed, any risks of the procedures,
possible benefits and possible alternative treatments. Once you understand the study, you
will be asked if you wish to participate; if so, you will be asked to sign this form.
Description of Procedures
If you are interested in participating, you will be asked questions about your health
and habits to determine if you are eligible. Information collected will include your age,
gender, race, functional capabilities and symptoms, other medical conditions current and
prior, medications, fluid intake, and use of cigarettes, alcohol, and dentures. Before the
study begins you will meet with a member of the research team who will instruct you to
complete three different questionnaires to assess your level of thirst and dry mouth.
Everyone will have 2 weeks of each treatment, namely chewing gum and artificial
saliva. The order in which you receive these interventions will be randomly assigned in
order to have the same number of participants in either intervention group at a time. After
the first intervention period, there will be a 2-week “washout” period during which you
will not use any tool to help with dry mouth. The purpose of this is to ensure the effect of
the first treatment you used does not carry over when you begin the next. During the two,
2-week intervention time periods you will utilize the gum or saliva spray before each meal
and before bedtime, as well as any other time during the day when you need it. We will
require that you complete the three aforementioned surveys a total of four more times
during the trial: before and after each 2-week intervention period. You will also be asked
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to complete a form describing how well you adhered to using the treatments at the end of
each intervention time period.
The researcher collecting information from you via these surveys will not know
which intervention you are currently using. We ask that you do not disclose this
information to them, or to other participants. This is an important aspect of clinical
research called “blinding”, which helps to ensure that the information we collect is free
from any bias, whether intentional or unintentional. You should be aware that once the
trial begins, you will only be identified by a specific number that holds no personal
identifying information. Although you are agreeing to allow the primary research team
access to your medical record for verification purposes, everyone involved will have been
trained on The Health Insurance Portability and Accountability Act (HIPAA) laws and
these will be strictly enforced to ensure your privacy.
A description of this clinical trial will be available on
http://www.ClinicalTrials.gov, as required by U.S. Law. This web site will not include
information that can identify you. At most, the web site will include a summary of the
results. You can search this web site at any time.
Risks and Inconveniences
It is important to know that you have the right to discontinue participating in this
trial at any time. The risks and side effects associated with these interventions are minimal
and include nausea, stomach upset, jaw tiring, and worsening or non-improvement of
symptoms. None of these negative events are life threatening or permanent. Staff will be
on hand to field any questions or concerns you may have and to document any side effects
you wish to report.
As with all studies, there is a small risk of loss of confidentiality. The procedures
in place to prevent this have been previously mentioned and every effort will be made to
keep your information confidential, however this cannot be guaranteed.
Utilizing the interventions as instructed, and presenting for a total of five in-person
meetings for data collection are the main inconveniences you will be faced with. The
meetings will be a maximum of 30 minutes each, separated by the span of two weeks.
Benefits
Benefits of participating in this study may include improvement of the thirst
and/or dry mouth symptoms you are experiencing.
Economic Considerations
The chewing gum and saliva spray will be provided at no cost to the participant.
There is no direct compensation offered to those who agree to participate. You can expect
a minimal expense to be incurred for traveling to your usual heart failure clinic a total of
five times throughout six weeks.
Treatment Alternatives/Alternatives
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There are no validated or well-studied options for thirst symptom management.
Some home remedies used by other patients (besides drinking water) include drinking
buttermilk or sucking on ice or hard candy. We are focusing this study on the chosen
interventions because we believe they have the potential to be more effective than other
options, without increasing the amount of water you take in daily, a common concern in
patients with heart failure.
Confidentiality and Privacy
Under no circumstances will your information be released to outside parties
without your explicit consent. Any identifiable information that is obtained from you
during the course of this study will remain confidential and will only be disclosed without
your explicit consent in the case of abuse or reportable diseases, as required by law. All
data collection forms and questionnaires will be kept in a locked file cabinet in the locked
office of the principle investigator. After all data has been analyzed, paper records will
be shredded and destroyed in accordance with HIPAA requirements. When the results of
this research are published or discussed in any forum, no information will be included
that would reveal your identity unless you specifically consent to this. Representatives
from Yale University, the Yale Human Research Protection Program and the Yale Human
Investigation Committee (the committee that reviews, approves, and monitors research on
human subjects), who are responsible for ensuring research compliance, may have access to
your information during the course of the study. These individuals are required to keep all
information confidential.
You have the right to review and copy your health information in your medical
record in accordance with institutional medical records policies.
This authorization to use and disclose your health information collected during your
participation in this study will never expire.
In Case of Injury
If you are injured while on study, seek treatment and contact the study doctor as
soon as you are able. Yale School of Medicine and Yale New Haven Hospital do not
provide funds for the treatment of research-related injury. If you are injured as a result of
your participation in this study, treatment will be provided. You or your insurance carrier
will be expected to pay the cost of this treatment. No additional financial compensation
for injury or lost wages is available.
You do not give up any of your legal rights by signing this form.
Voluntary Participation and Withdrawal
Participating in this study is voluntary. You are free to choose not to take part in
this study. Refusing to participate will involve no penalty or loss of benefits to which
you are otherwise entitled (such as your health care outside the study, the payment for
your health care, and your health care benefits). However, you will not be able to enroll
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in this research study and will not receive study procedures as a study participant if you
do not allow use of your information as part of this study.
If you do become a subject, you are free to stop and withdraw from this study at
any time during its course. To withdraw from the study, you can call a member of the
research team at any time and tell them that you no longer want to take part. This will
cancel any future appointments. The researchers may withdraw you from participating in
the research if necessary due to worsening medical condition, development of serious
side effects, or subject non-compliance.
Withdrawing from the study will involve no penalty or loss of benefits to which
you are otherwise entitled. It will not harm your relationship with your own doctors or
with Yale School of Medicine or Yale-New Haven Hospital.
You may withdraw or take away your permission to use and disclose your health
information at any time. You may withdraw your permission by telling the study staff or
by writing to the principal investigator. If you withdraw your permission, you will not be
able to stay in this study. When you withdraw your permission, no new health
information identifying you will be gathered after that date. Information that has already
been gathered may still be used and given to others until the end of the research study, as
necessary to ensure the integrity of the study and/or study oversight.
Questions
We have used some technical terms in this form. Please feel free to ask about
anything you don't understand and to consider this research and the consent form carefully
– as long as you feel is necessary – before you make a decision.
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Authorization and Permission
I have read (or someone has read to me) this form and have decided to participate
in the project described above. Its general purposes, the particulars of my involvement and
possible hazards and inconveniences have been explained to my satisfaction. My signature
also indicates that I have received a copy of this consent form.
By signing this form, I give permission to the researchers to use information about
me for the purposes described in this form. By refusing to give permission, I understand
that I will not be able to be in this research.
Name of Subject:_____________________________

Signature:___________________________________
Date:______________________________________
___________________________________________
Signature of Principal Investigator
or
___________________________________________
Signature of Person Obtaining Consent

___________________
Date
___________________
Date

If after you have signed this form you have any questions about your privacy
rights, please contact the Yale Privacy Officer at 203-432-5919.
If you have further questions about this project or if you have a research-related
problem, you may contact the Principal Investigators Matthew M. Burg, PhD at 203-9325711 or Alison Robb, PA-SII at 315-247-1566. If you would like to talk with someone
other than the researchers to discuss problems, concerns, and questions you may have
concerning this research, or to discuss your rights as a research subject, you may contact
the Yale Human Investigation Committee at 203-785-4688.
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